Volume 43 Issue 3 September 2026

E-ISSN: 1308-5263

Turkish Journal of Hematology

The Official Journal of the Turkish Society of Hematology

Research Articles

Liver and Spleen Point Shear-Wave Elastography in Newly Diagnosed *BCR::ABL1*-Negative Myeloproliferative Neoplasms: Associations with Hematological Parameters and Bone Marrow Fibrosis Grade - A Prospective Cross-Sectional Study

Mehmet Taha Avcı, Melda Cömert, Demet Kiper, Gülgün Kavukçu, Ayhan Dönmez, Sadık Tamsel, Mine Hekimgil, Nazan Özsan, Süha Süreyya Özbek; İzmir, Türkiye

Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort Study

Shiqi Sun, Zejing Huang, Yunlong Tang, Weiying Gu, Leilei Wu, Fujun Shen; Yancheng, Suzhou, P.R. China

Is CMV PCR Monitoring Necessary in Patients with Hematological Malignancy Receiving Chemotherapy? A Prospective Single-Center Study

Zeynep Tuğba Karabulut, Tevfik Dündar, Serhat Çelik, Muzaffer Keklik, Ali Ünal, Selma Gökahmetoğlu, Leylagül Kaynar; Adana, Ankara, Kayseri, İstanbul, Türkiye

Asparaginase-Based Treatment Modifications and Their Effect on Pediatric Acute Lymphoblastic Leukemia Outcomes: A Single-Center Experience

Fatma Burçin Kurtipek, Dilek Kaçar, Turan Bayhan, Ayça Koca Yozgat, Özlem Arman Bilir, Namık Yaşar Özbek, Hüsniye Neşe Yaralı; Ankara, Türkiye

Role of ^{18}F-FDG PET/CT Metabolic Parameters in Treatment Response Evaluation and Prognostic Assessment of Hodgkin Lymphoma: A Retrospective Analysis

Hatice Uysal, Aziz Gültekin, Nil Güler, Nilay Şen Türk, Fikri Selçuk Şimşek, Tarık Şengöz, Doğangün Yüksel; Antalya, Denizli, Türkiye

Perspectives in Hematology

Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven Treatment

Vildan Özkocaman, Tuğcan Alp Kırkızlar, Gökhan Metan, Ömrüm Uzun, İbrahim Ethem Pınar, Fahir Özkalemkaş, Muhlis Cem Ar, Murat Akova; Bursa, Edirne, Ankara, İstanbul, Türkiye

Anticoagulation in Advanced Chronic Kidney Disease: Navigating Uncertainty

Arzu Velioğlu; İstanbul, Türkiye



Cover Picture:

Hemolytic Anemia in a Newborn: Thinking About Infantile Pyknocytosis

Ines Maaloul, Ines Jedidi, Fatma Charfi, Imen Krichen, Nour Louati, Thouraya Kamoun

3

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

EDITORIAL BOARD

Editor-in-Chief

Reyhan Küçükkaya
ORCID ID: https://orcid.org/0000-0001-5814-7118

Associate Editors

Ali İrfan Emre Tekgündüz
Memorial Bahçelievler Hospital, Adult Hematology and BMT Clinic, İstanbul, Türkiye
ORCID ID: 0000-0001-9967-2357

Ayşegül Ünüvar
İstanbul University, İstanbul School of Medicine, Division of Pediatric Hematology-Oncology, İstanbul, Türkiye
ORCID ID: 0000-0002-4730-7697

Deniz Gören
Haliç University Faculty of Medicine; Memorial Şişli Hospital, Department of Hematology, İstanbul, Türkiye
ORCID ID: 0000-0002-3189-6810

Ebru Koca
Başkent University Ankara Hospital, Clinic of Hematology, Ankara, Türkiye
ORCID ID: 0000-0002-7566-4456

Hale Ören
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Türkiye
ORCID ID: 0000-0001-5760-8007

İnci Alacacıoğlu
İzmir Katip Çelebi University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İzmir, Türkiye
ORCID ID: 0000-0002-8187-7159

Muhlis Cem Ar
İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye
ORCID ID: 0000-0002-0332-9253

Müge Sayitoğlu
İstanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, İstanbul, Türkiye
ORCID ID: 0000-0002-8648-213X

Şule Ünal
Hacettepe University Faculty of Medicine, Division of Pediatric Hematology, Ankara, Türkiye
ORCID ID: 0000-0002-3842-8788

Past Editors
Erich Frank
Orhan Ulutin
Hamdi Akan
Aytemiz Gürgey

Language Editor
Leslie Demir

Statistic Editor
Hülya Ellidokuz

Media Director
Bengü Timoçin Efe

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

Contact Information

Editorial correspondence should be addressed to Dr. Reyhan Küçükkaya
E-mail: rkucukkaya@hotmail.com

All Inquiries Should be Addressed to

TURKISH JOURNAL OF HEMATOLOGY

Address : Turan Güneş Bulv. İlkbahar Mah. Fahreddin Paşa Sokağı (eski 613. Sok.) No: 8 06550 Çankaya, Ankara / Türkiye
Phone : +90 312 490 98 97
Fax : +90 312 490 98 68
E-mail : system@tjh.com.tr

E-ISSN: 1308-5263

Publishing Manager

Reyhan Küçükkaya

Management Address

Turkish Society of Hematology
Turan Güneş Bulv. İlkbahar Mah. Fahreddin Paşa Sokağı (eski 613. Sok.) No: 8 Çankaya - Ankara - Türkiye

Online Manuscript Submission

https://jag.journalagent.com/tjh/

Web Page

www.tjh.com.tr

Owner on Behalf of the Turkish Society of Hematology

Özgür Mehtap

Publishing House

Molla Gürani Mah. Kaçamak Sk. No: 21,
34093 Fındıkzade, İstanbul / Türkiye
Tel: +90 530 177 30 97
E-mail: info@galenos.com.tr
Publisher Certificate Number: 14521

Publication Date

01.09.2026

Cover Picture

Hemolytic Anemia in a Newborn: Thinking About Infantile Pyknocytosis

Peripheral blood smear showing anisocytosis and poikilocytosis with distinctive abnormalities including numerous pyknocytes, polychromasia, fragmented red cells, and microspherocytes.

International scientific journal published quarterly.

The Turkish Journal of Hematology is published by the commercial enterprise of the Turkish Society of Hematology with Decision Number 6 issued by the Society on 7 October 2008.

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

AIMS AND SCOPE

The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology.

Submissions of manuscripts to TJH, evaluation of the manuscripts by the referees, and all publication stages are completely free of charge.

All publications of TJH can be accessed free of charge online at www.tjh.com.tr. Thus, it is possible for a wide audience to read your work.

The Editorial Board of the Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT), and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).

The aim of the Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, the Turkish Journal of Hematology does not accept case reports. Articles consisting solely of computational analyses and meta-analyses without validation with primary biological samples (blood, bone marrow, stem cells) are also not within the scope of this journal.

General practitioners interested in hematology and internal medicine specialists are among our target audience, and the Turkish Journal of Hematology aims to publish according to their needs. The Turkish Journal of Hematology is indexed, as follows:

- PubMed Medline
- PubMed Central
- Science Citation Index Expanded
- EMBASE
- Scopus
- CINAHL
- Gale/Cengage Learning
- EBSCO
- Gale
- ProQuest
- Index Copernicus
- Tübitak/Ulakbim Turkish Medical Database
- Turk Medline
- Hinari
- GOALI
- ARDI
- OARE
- DOAJ

2025 Impact Factor: 1.6

Digital Archiving and Preservation Policy

Digital preservation is a set of processes and activities that ensure the retrieval and distribution of information now available in digital formats to guarantee long-term, perpetual access. The preservation policy includes the following measures:

Website Archiving

All of the electronic content (website, manuscript, etc.) is stored in three different sources. Content on a server is online and accessible to readers. A copy of the same content is preserved as a backup on other servers. Should a server fail, other resources can be brought online and the website is expected to be available in 24-36 hours.

Abstracting/Indexing Services

Our journal's abstracting/indexing services store essential information about articles. In addition, some of our journals' abstracting/indexing services archive metadata about the article and electronic versions of the articles. In this way, copies of articles are presented to the scientific community through these systems as an alternative to journals. This journal's archive has been backed up by PubMed Central as of the 2012 publications.

Cessation of Publication

If this journal must stop publishing, the articles will remain online and accessible to readers through third parties and archiving processes such as those described above. Content can be accessed through PORTICO when required under certain circumstances, such as if collection is stopped.

Author Self-Archiving Policy

Abstract and Citation Information

Authors may reuse the abstract and citation information (e.g. title, author name, publication dates) of their article anywhere at any time including social media such as Facebook, blogs, and Twitter, provided that where possible a link is included back to the article on the Turkish Journal of Hematology website.

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

Accepted Manuscript

The "accepted manuscript" is the final draft of the author's manuscript, as accepted for publication by a journal, including modifications based on referees' suggestions, before it has undergone copyediting, typesetting, and proof correction.

Authors of open access articles are free to post and share their links anywhere immediately upon publication.

Subscription Information

The Turkish Journal of Hematology is sent free-of-charge to members of the Turkish Society of Hematology and libraries in Türkiye and abroad. Hematologists, other medical specialists that are interested in hematology, and academicians could subscribe for only 40 $ per published issue. All published volumes are available in full text free-of-charge online at www.tjh.com.tr.

Address: Turan Güneş Bulv. İlkbahar Mah. Fahreddin Paşa Sokağı (eski 613. Sok.) No: 8 Çankaya - ANKARA, Türkiye

Telephone: +90 312 490 98 97

Fax: +90 312 490 98 68

Online Manuscript Submission: https://jag.journalagent.com/tjh/

Web page: www.tjh.com.tr

E-mail: system@tjh.com.tr

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. Open Access Policy is based on the rules of the Budapest Open Access Initiative (BOAI): http://www.budapestopenaccessinitiative.org/. By "open access" to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles; crawl them for indexing; pass them as data to software; or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License.

CC BY-NC-ND: This license allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

CC BY-NC-ND includes the following elements:

BY – Credit must be given to the creator

NC – Only noncommercial uses of the work are permitted

ND – No derivatives or adaptations of the work are permitted

Permission Requests

Permission is required for the use of any material published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND) International License for commercial purposes (selling, etc.), in order to protect the rights of the copyright owner and the author(s). Republication and reproduction of images or tables in any published material should be done with proper citation of source providing authors' names; article title; journal title; year (volume) and page of publication; copyright year of the article.

Permissions

Requests for permission to reproduce published material should be sent to the editorial office.

Editor: Professor Dr. Reyhan Diz Küçükkaya

Address: Turan Güneş Bulv. İlkbahar Mah. Fahreddin Paşa Sokağı (eski 613. Sok.) No: 8 Çankaya - ANKARA, Türkiye

Telephone: +90 312 490 98 97

Fax: +90 312 490 98 68

Online Manuscript Submission: https://jag.journalagent.com/tjh/

Web page: www.tjh.com.tr

E-mail: system@tjh.com.tr

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Publisher

Galenos Yayınevi

Molla Gürani Mah. Kaçamak Sk. No:21 34093 Fındıkzade-İstanbul

Telephone: 0212 621 99 25

E-mail: info@galenos.com.tr

Instructions for Authors

Instructions for authors are published in the journal and at www.tjh.com.tr

Material Disclaimer

Authors are responsible for the manuscripts they publish in the Turkish Journal of Hematology. The editor, editorial board, and publisher do not accept any responsibility for published manuscripts.

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

If you use a table or figure (or some data in a table or figure) from another source, cite the source directly in the figure or table legend.

Editorial Policy

Following receipt of each manuscript, a checklist is completed by the Editorial Assistant. The Editorial Assistant checks that each manuscript contains all required components and adheres to the author guidelines, after which time it will be forwarded to the Editor in Chief. Following the Editor in Chief's evaluation, each manuscript is forwarded to an associate editor, who in turn assigns reviewers. Generally, all manuscripts will be reviewed by at least three reviewers selected by the associate editor, based on their relevant expertise. The associate editor could also be assigned as a reviewer along with the reviewers. After the reviewing process, all manuscripts are evaluated in an editorial board meeting.

The Turkish Journal of Hematology's Editor in Chief and editorial board members are active researchers. It is possible that they would desire to submit their manuscript to the Turkish Journal of Hematology. This may be creating a conflict of interest. These manuscripts will not be evaluated by the submitting editor(s). The review process will be managed and decisions will be made by the Editor in Chief, acting independently. In some situation, this process will be overseen by an outside independent expert in reviewing submissions from editors.

Advertising Policy

The Turkish Journal of Hematology is the official journal of the Turkish Society of Hematology, which is the financial supporter of the journal.

Advertising fees are transferred to the Turkish Society of Hematology, which are used for publishing expenses of the journal.

This journal's advertising sales and editorial processes are separated to ensure editorial independence and reduce the effects of financial interests.

Current or potential sponsors and advertisers do not affect editorial decisions of the journal. Advertisers and sponsors have no control or influence over the results of a user's website searches.

Advertisements should not be deceptive or misleading and must be verifiable. Excessive or exaggerated expressions are not allowed.

If the text or image contains inappropriate or offensive content or is about personal, racial, ethnic, sexual orientation or religious content, these advertisements are not accepted.

Advertisers are responsible for ensuring that their advertisements comply with applicable laws regarding deceptive and/or offensive content and ethical issues.

Drug and medical product advertisements can be presented on the cover pages of the journal, separately from the published scientific content and without page numbers.

The published advertisements are direct and clearly distinguishable from the editorial content.

OPEN ACCESS

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

INSTRUCTIONS FOR AUTHORS

The Turkish Journal of Hematology accepts invited review articles, research articles, brief reports, letters to the editor, and hematological images that are relevant to the scope of hematology, on the condition that they have not been previously published elsewhere. Basic science manuscripts, such as randomized, cohort, cross-sectional, and case control studies, are given preference. Articles consisting solely of computational analyses and meta-analyses without validation with primary biological samples (blood, bone marrow, stem cells) are not within the scope of this journal. All manuscripts are subject to editorial revision to ensure they conform to the style adopted by the journal. The reviewing system is double-blind.

Manuscripts should be prepared according to ICMJE guidelines. Original manuscripts require a structured abstract. Label each section of the structured abstract with the appropriate subheading (Objective, Materials and Methods, Results, and Conclusion). Letters to the editor do not require an abstract. Research or project support should be acknowledged as a footnote on the title page. Technical and other assistance should be provided on the title page.

Submissions and publication are free of charge.

Original Manuscripts

Title Page

Title: The title should provide important information regarding the manuscript's content. The title must specify that the study is a cohort study, cross-sectional study, case control study, or randomized study (i.e. Cao GY, Li KX, Jin PF, Yue XY, Yang C, Hu X. Comparative bioavailability of ferrous succinate tablet formulations without correction for baseline circadian changes in iron concentration in healthy Chinese male subjects: A single-dose, randomized, 2-period crossover study. Clin Ther. 2011; 33: 2054-2059).

The title page should include the authors' names, degrees, and institutional/professional affiliations and a short title, abbreviations, keywords, financial disclosure statement, and conflict of interest statement. If a manuscript includes authors from more than one institution, each author's name should be followed by a superscript number that corresponds to their institution, which is listed separately. Please provide contact information for the corresponding author, including name, e-mail address, and telephone and fax numbers.

Important Notice: The title page should be submitted separately.

Running Head: The running head should not be more than 40 characters, including spaces, and should be located at the bottom of the title page.

Word Count: The word count of a manuscript, excluding the abstract, acknowledgments, figure and table legends, and references, should not exceed 2500 words. The word count of an abstract should not exceed 300 words.

Conflict-of-Interest Statement: To prevent potential conflicts of interest from being overlooked, this statement must be included in each manuscript. In case there are conflicts of interest, every author should complete the ICMJE general declaration form.

Abstract and Keywords: The second page should include an abstract that does not exceed 300 words. For manuscripts sent by authors in Türkiye, a title and abstract in Turkish are also required. As most readers read the abstract first, it is critically important. Moreover, as various electronic databases integrate only abstracts into their index, important findings should be presented in the abstract.

Objective: The abstract should state the objective (the purpose of the study and hypothesis) and summarize the rationale for the study.

Materials and Methods: Important methods should be written respectively.

Results: Important findings and results should be provided here.

Conclusion: The study's new and important findings should be highlighted and interpreted.

Other types of manuscripts, such as reviews, perspectives, and editorials, will be published according to uniform requirements. Provide 3-10 keywords below the abstract to assist indexers. Use terms from the Index Medicus Medical Subject Headings List (https://www.nlm.nih.gov/mesh/meshhome.html). For randomized studies, a CONSORT abstract should be provided (http://www.consort-statement.org/).

Introduction: The introduction should include an overview of the relevant literature presented in summary form (one page), and the issues that remain interesting, unique, problematic, relevant, or unknown about the topic must be specified. The introduction should conclude with the rationale for the study, its design, and its objective(s).

Materials and Methods: Clearly describe the selection of observational or experimental participants, such as patients, laboratory animals, and controls, including inclusion and exclusion criteria and a description of the source population. Identify the methods and procedures in sufficient detail to allow other researchers to reproduce your results. Provide references to established methods (including statistical methods), provide references to brief modified methods, and provide the rationale for using them and an evaluation of their limitations. Identify all drugs and chemicals used, including generic names, doses, and routes of administration. The section should include only information that was available at the time the plan or protocol for the study was devised (https://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_combined.pdf).

Statistics: Describe the statistical methods used in enough detail to enable a knowledgeable reader with access to the original data to verify

the reported results. Statistically important data should be given in the text, tables, and figures. Provide details about randomization, describe treatment complications, provide the number of observations, and specify all computer programs used.

Results: Present your results in logical sequence in the text, tables, and figures. Do not present all the data provided in the tables and/or figures in the text; emphasize and/or summarize only important findings, results, and observations in the text. For clinical studies provide the number of samples, cases, and controls included in the study. Discrepancies between the planned number and obtained number of participants should be explained. Comparisons and statistically important values (i.e. p value and confidence interval) should be provided.

Discussion: This section should include a discussion of the data. New and important findings/results and the conclusions they lead to should be emphasized. Link the conclusions with the goals of the study, but avoid unqualified statements and conclusions not completely supported by the data. Do not repeat the findings/results in detail; important findings/results should be compared with those of similar studies in the literature, along with a summarization. In other words, similarities or differences in the obtained findings/results with those previously reported should be discussed.

Study Limitations: Limitations of the study should be detailed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.

Conclusion: The conclusion of the study should be highlighted.

References

Cite references in the text, tables, and figures with numbers in square brackets. Number references consecutively according to the order in which they first appear in the text. Journal titles should be abbreviated according to the style used in Index Medicus (consult List of Journals Indexed in Index Medicus). Include among the references any paper accepted for publication but not yet published, designating the journal followed by "in press."

Examples of References:

1. List all authors

Deeg HJ, O'Donnel M, Tolar J. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure immunosuppressive therapy. Blood. 2006;108:1485-1491.

2. Organization as author

Royal Marsden Hospital Bone Marrow Transplantation Team. Failure of syngeneic bone marrow graft without preconditioning in post-hepatitis marrow aplasia. Lancet. 1977;2:742-744.

3. Book

Wintrobe MM. Clinical Hematology, 5th ed. Philadelphia, Lea & Febiger, 1961.

4. Book Chapter

Perutz MF. Molecular anatomy and physiology of hemoglobin. In: Steinberg MH, Forget BG, Higs DR, Nagel RI (eds). Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management. New York, Cambridge University Press, 2000.

5. Abstract

Drachman JG, Griffin JH, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation. Blood. 1994;84:390a (abstract).

6. Letter to the Editor

Rao PN, Hayworth HR, Carroll AJ, Bowden DW, Pettenati MJ. Further definition of 20q deletion in myeloid leukemia using fluorescence in situ hybridization. Blood. 1994;84:2821-2823.

7. Supplement

Alter BP. Fanconi's anemia, transplantation, and cancer. Pediatr Transplant. 2005;9(Suppl 7):81-86.

Brief Reports

Abstract length: Not to exceed 150 words.

Article length: Not to exceed 1200 words.

Introduction: State the purpose and summarize the rationale for the study.

Materials and Methods: Clearly describe the selection of the observational or experimental participants. Identify the methods and procedures in sufficient detail. Provide references to established methods (including statistical methods), provide references to brief modified methods, and provide the rationale for their use and an evaluation of their limitations. Identify all drugs and chemicals used, including generic names, doses, and routes of administration.

Statistics: Describe the statistical methods used in enough detail to enable a knowledgeable reader with access to the original data to verify the reported findings/results. Provide details about randomization, describe treatment complications, provide the number of observations, and specify all computer programs used.

Results: Present the findings/results in a logical sequence in the text, tables, and figures. Do not repeat all the findings/results in the tables and figures in the text; emphasize and/or summarize only those that are most important.

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

Discussion: Highlight the new and important findings/results of the study and the conclusions they lead to. Link the conclusions with the goals of the study, but avoid unqualified statements and conclusions not completely supported by your data.

Invited Review Articles

Abstract length: Not to exceed 300 words.

Article length: Not to exceed 4000 words.

Review articles should not include more than 100 references. Reviews should include a conclusion, in which a new hypothesis or study about the subject may be posited. Do not publish methods for literature search or level of evidence. Authors who submit review articles should have already published research articles on the relevant subject. The study's new and important findings should be highlighted and interpreted in the Conclusion section. There should be a maximum of two authors for review articles.

Review articles are solicited by the Editor in Chief. Authors wishing to submit an unsolicited review article should contact the Editor in Chief prior to submission in order to screen the proposed topic for relevance and priority.

Perspectives in Hematology

"Perspectives" are invited articles discussing significant topics relevant to hematology. They are more personal than a review article. Authors wishing to submit a Perspectives in Hematology article should contact the Editor in Chief prior to submission in order to screen the proposed topic for relevance and priority. These submissions must advance the hot subjects of experimental and/or clinical hematology beyond the articles previously published or in press in TJH. Perspective papers should meet the restrictive criteria of TJH regarding unique scientific and/or educational value, which will impact and enhance clinical hematology practice or the diagnostic understanding of blood diseases. Priority will be given to such manuscripts based upon the prominence, significance, and timeliness of the content. The submitting author must already be an expert with recognized significant published scientific experience in the specific field related to the "Perspectives" article. There should be a maximum of two authors per "Perspectives" submission.

These manuscripts are published by invitation only.

Abstract length: Not to exceed 150 words.

Article length: Not to exceed 1000 words.

References: Should not include more than 50 references.

Images in Hematology

Article length: Not exceed 200 words.

Authors can submit for consideration illustrations or photos that are interesting, instructive, and visually attractive, along with a few lines of explanatory text and references. Images in Hematology can include no more than 200 words of text, 5 references, and 3 figures or tables. No abstract, discussion, or conclusion is required. A brief running title is required.

Letters to the Editor

Article length: Not to exceed 500 words.

Letters can include no more than 500 words of text, 5-10 references, and 1 figure or table. No abstract is required, but please include a brief title. The total number of authors is usually limited to a maximum of 5 for letters to the editor.

Editorials

Editorials are invited articles addressing topics of particular relevance to hematology, important developments in the field, or historical and institutional subjects related to the journal or the discipline. These manuscripts are published by invitation only.

Abstract: No abstract is required.

Article length: Not to exceed 2500 words.

References: Should not include more than 20 references.

Figures and Tables: A maximum of 4 figures and/or tables may be included.

Subheadings may be used when appropriate to the content.

Tables

Supply each table in a separate file. Number tables according to the order in which they appear in the text and supply a brief caption for each. Give each column a short or abbreviated heading. Write explanatory statistical measures of variation, such as standard deviation or standard error of mean. Be sure that each table is cited in the text.

Figures

Figures should be professionally drawn and/or photographed. Authors should number figures according to the order in which they appear in the text. Figures include graphs, charts, photographs, and illustrations. Each figure should be accompanied by a legend that does not exceed 50 words. Use abbreviations only if they have been introduced in the text. Authors are also required to provide the level of magnification for histological slides. Explain the internal scale and identify the staining method used. Figures should be submitted as separate files, not in the text file. High-resolution image files are not preferred for initial submission as the file sizes may be too large. The total file size of the PDF for peer review should not exceed 5 MB.

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

Authorship

Each author should have participated sufficiently in the work to assume public responsibility for the content. Any portion of a manuscript that is critical to its main conclusions must be the responsibility of at least 1 author.

Contributor's Statement

All submissions should contain a contributor's statement page. Each author should have made substantial contributions to the idea and design, acquisition of data, or analysis and interpretation of findings. All persons designated as an author should qualify for authorship, and all those that qualify should be listed. Each author should have participated sufficiently in the work to take responsibility for appropriate portions of the text.

Acknowledgments

Acknowledge support received from individuals, organizations, grants, corporations, and any other source. For work involving a biomedical product or potential product partially or wholly supported by corporate funding, a note stating, "This study was financially supported (in part) with funds provided by (company name) to (authors' initials)", must be included. Grant support, if received, needs to be stated and the specific granting institutions' names and grant numbers provided when applicable.

Authors are expected to disclose on the title page any commercial or other associations that might pose a conflict of interest in connection with the submitted manuscript. All funding sources that supported the work and the institutional and/or corporate affiliations of the authors should be acknowledged on the title page.

Conditions of Publication

All authors are required to affirm the following statements before their manuscript is considered: 1. The manuscript is being submitted only to the Turkish Journal of Hematology; 2. The manuscript will not be submitted elsewhere while under consideration by the Turkish Journal of Hematology; 3. The manuscript has not been published elsewhere, and should it be published in the Turkish Journal of Hematology it will not be published elsewhere without the permission of the editors (these restrictions do not apply to abstracts or to press reports for presentations at scientific meetings); 4. All authors are responsible for the manuscript's content; 5. All authors participated in the study concept and design, analysis and interpretation of the data, and drafting or revising of the manuscript and have approved the manuscript as submitted. In addition, all authors are required to disclose any professional affiliation, financial agreement, or other involvement with any company whose product figures prominently in the submitted manuscript.

Authors of accepted manuscripts will receive electronic page proofs and are responsible for proofreading and checking the entire article within two days. Failure to return the proof in two days will delay publication. If the authors cannot be reached by email or telephone within two weeks, the manuscript will be rejected and will not be published in the journal.

Copyright

At the time of submission all authors will receive instructions for submitting an online copyright form. No manuscript will be considered for review until all authors have completed their copyright form. Please note that it is our practice not to accept copyright forms via fax, e-mail, or postal service unless there is a problem with the online author accounts that cannot be resolved. Every effort should be made to use the online copyright system. Corresponding authors can log in to the submission system at any time to check the status of any co-author's copyright form.

Note: We cannot accept any copyright that has been altered, revised, amended, or otherwise changed. Our original copyright form must be used as is.

Author Rights

Authors can use their articles, in full or in part, for scholarly, non-commercial purposes and with the condition of attribution such as:

Use by an author in the author's classroom education (including distribution of documents, paper or electronic)

Distribution of documents (including through e-mail) to known research colleagues for their personal use (but not for commercial use)

Inclusion in a thesis or dissertation (provided that this is not to be published commercially)

Use in a subsequent compilation of the author's work

Preparation of other derivative works (but not for commercial use)

Otherwise using or re-using portions or excerpts in other works

Units of Measurement

Measurements should be reported using the metric system, according to the International System of Units (SI). Consult the SI Unit Conversion Guide, New England Journal of Medicine Books, 1992.

An extensive list of conversion factors can be found at https://www.nist.gov/itl/ssd/software-quality-group/metrics-and-measures#Metrics_vs._Measures. For more details, see the examples for CBC at https://www.amamanualofstyle.com/page/si-conversion-calculator.

Abbreviations and Symbols

Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for an abbreviation should precede its first use in the text, unless it is a standard abbreviation. All acronyms

used in the text should be defined at first mention, followed by the abbreviation in parentheses; thereafter, only the acronym should appear in the text. Acronyms may be used in the abstract if they occur 3 or more times therein, but must be reintroduced in the body of the text. Generally, abbreviations should be limited to those defined in the AMA Manual of Style, current edition. A list of each abbreviation (and the corresponding full term) used in the manuscript must be provided on the title page.

Search Engine Optimization Policy

Authors should follow the relevant guidelines to enhance the visibility of their articles.

Keywords should consist of terms from the Medical Subject Headings (MeSH). MeSH is a standardized index of subject headings used in medical literature and is recommended by many international journals for selecting keywords.

https://www.nlm.nih.gov/mesh/meshhome.html

Use of Large Language Models and Generative AI Tools

"AI tools cannot meet the requirements for authorship as they cannot take responsibility for the submitted work. As non-legal entities, they cannot assert the presence or absence of conflicts of interest nor manage copyright and license agreements. Authors who use AI tools in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, must be transparent how the AI tool was used and which tool was used. Authors are fully responsible for the content of their manuscript, even those parts produced by an AI tool, and are thus liable for any breach of publication ethics." COPE Position Statement on Authorship and AI Tools. Detailed information about the statement can be accessed at https://publicationethics.org/cope-position-statements/ai-author.

After reviewing the COPE statement given above, the editors of the Turkish Journal of Hematology decided that papers should include a statement in a section titled "Declaration Regarding the Use of AI and AI-Assisted Technologies" to inform readers if AI or AI-assisted tools were used in the writing process. It is important to remember that all authors are responsible for the content of their work. This declaration does not apply to the use of basic tools for checking grammar, spelling, or references (such as Mendeley, EndNote, Zotero, and others). If there is nothing to declare, there is no need to add a statement.

It is suggested that authors follow this format when preparing their statement:

During the preparation of this work, the author(s) utilized [NAME OF TOOL(S) USED] to [DESCRIPTION OF HOW THE TOOL(S) WERE UTILIZED AND HOW THE VALIDITY OF THE OUTPUTS WAS EVALUATED]. After carefully reviewing and editing the content as necessary, full responsibility for the publication's content is taken by the author(s). This incorporation of AI tool usage primarily impacted [SPECIFY WHICH ASPECTS OF THE STUDY, ARTICLE CONTENTS, DATA, OR SUPPORTING FILES WERE AFFECTED/GENERATED].

Example:

During the preparation of this work, the author(s) utilized **OpenAI's ChatGPT** to **generate summaries of research articles related to the topic. These summaries were evaluated by comparing them to manually written summaries by experts in the field. Upon confirming the accuracy and relevance of the generated summaries, they were integrated into the literature review section of the manuscript.** After carefully reviewing and editing the content as necessary, full responsibility for the publication's content is taken by the author(s). This incorporation of AI tool usage primarily impacted **the efficiency of the literature review process and the comprehensiveness of the gathered research insights**.

Online Manuscript Submission Process

The Turkish Journal of Hematology uses submission software powered by JournalAgent. The website for submissions to the Turkish Journal of Hematology is https://jag.journalagent.com/tjh/. This system is quick and convenient for both authors and reviewers.

Setting up an Account

To submit a manuscript, new users must register and provide their account details. Please log in, or if this is your first time, click the "New User" button. To create a new account: After clicking "New User," fill in all the required fields. Your email address is especially important. Once you have entered all the necessary information, click "Save" to complete the registration.

If you already have an account but have forgotten your login details, go to the "Forgot your password?" section in the journal's online submission system. Enter your email address and "Write confirmation code." The system will then automatically send you a username and a new temporary password.

Detailed instructions and support are available on the website, and you can receive a username and password during your first visit. Full support is provided to authors. If you have any questions regarding manuscript submission to the journal, you may contact the journal manager at system@tjh.com.tr. For JournalAgent customer support, please click the link "Technical problems or questions: Please contact Author Support" located on the login page of the online submission system.

The Electronic Submission Process

Log in to the Author Center. After logging in, go to the "Author Section" in the menu bar, then select "Submit New Manuscript." Complete the

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

"Checklist" section. The manuscript submission process in the system consists of a total of 9 steps. On each screen, enter the required information and click "Save and Continue" to save your work and proceed to the next step.

Upload Files

Click on the "Choose File" button and locate the file on your computer. In the "File Tag" box above the "Choose File" button, enter the name of the file. When you have selected all the files you want to upload, click the "Upload" button. Review your submission before sending it to the journal. Click the "Send this manuscript to the Editorial Board" button when you are finished reviewing. You can use JournalAgent at any time to check the status of your submission. The journal's editorial office will inform you by e-mail once a decision has been made. Once your manuscript has been received by the journal, a technical check will be performed by the editorial office. If revisions are required, the author(s) will be asked to make the necessary corrections. If no revisions are needed, the manuscript will be forwarded to the Editor in Chief.

The Review Process

Each manuscript submitted to the Turkish Journal of Hematology is subject to an initial review by the editorial office in order to determine if it is aligned with the journal's aims and scope and complies with essential requirements. Manuscripts sent for peer review will be assigned to one of the journal's associate editors that has expertise relevant to the manuscript's content. After review, the reviewers' comments are sent to the associate editor, who then forwards their comments to the editor-in-chief for a preliminary decision. At this stage, based on the feedback from reviewers, manuscripts can be accepted or rejected, or revisions can be recommended. Following initial peer review, articles judged worthy of further consideration often require revision. Revised manuscripts generally must be received within 1 month of the date of the initial decision. Extensions must be requested from the associate editor at least 2 weeks before the 1-month revision deadline expires; the Turkish Journal of Hematology will reject manuscripts that are not received within the 1-month revision deadline. Manuscripts with extensive revision recommendations will be sent for further review, usually by the same reviewers, upon their re-submission. All accepted manuscripts are sent to a statistical and English language editor before publishing. Finally, the technical editor undertakes a final edit and a marked-up copy will be e-mailed to the corresponding author for review and to make any final adjustments.

Submission of Revised Papers

When revising a manuscript based on the reviewers' and editor's feedback, please insert all changed text in red. Please do not use track changes, as this feature can make reading difficult. To submit revised manuscripts, please log into your author center at JournalAgent. Your manuscript will be stored under "Manuscripts." When you click on the link, the system will guide you to create a revision. A revised manuscript number will be created for you; you will then continue by clicking on "Submission" for your revised manuscript. You will then be guided through a submission process very similar to that for new manuscripts. You will be able to amend any details you wish. In Step 9, upload the documents related to your revised manuscript. You will then need to review your paper as a PDF and click the "Send this manuscript to the Editorial Board" button. Your revised manuscript will have the same ID number as the original version, but with the addition of (1) at the end, such as TJH-01112 for an original and TJH-01112 (1), indicating a first revision; subsequent revisions will end with (2), (3), and so on. Please do not submit a revised manuscript as a new paper, as revised manuscripts are processed differently. If you click on the "Send this manuscript to the Editorial Board" button and receive a message stating that the revision option has expired, please contact the Editorial Assistant at system@tjh.com.tr to reactivate the option.

English Language and Statistical Editing

All manuscripts are professionally edited by an English language editor prior to publication.

After papers have been accepted for publication, manuscript files are forwarded to the statistical and English language editors before publishing. Editors will make changes to the manuscript to ensure it adheres to TJH requirements. Significant changes or concerns are referred to corresponding authors for editing.

Online Early

The Turkish Journal of Hematology publishes abstracts of accepted manuscripts online in advance of their publication. After an article has been accepted and edited, the authors have submitted the final corrections, and all changes have been applied, the article will be published online within 10 days. At that time the manuscript will receive a Digital Object Identifier (DOI) number. Authors of accepted manuscripts will receive electronic page proofs directly from the printer and are responsible for proofreading and checking the entire manuscript, including tables, figures, and references. Page proofs must be returned within 48 hours to avoid delays in publication.

Preprint Policy

The Turkish Journal of Hematology does not accept manuscripts that have been previously submitted to or posted on preprint servers. Any manuscript that has been made publicly available as a preprint, regardless of the platform or DOI assignment, is considered to have undergone prior publication and is therefore ineligible for submission to this journal.

To ensure adherence to this policy, authors are required to confirm during submission that their manuscript has not been deposited on any preprint server or made publicly available in any similar format prior to submission.

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

CONTENTS

Editorial

198 75 Years of Adventure in Turkish Scientific Medical Publishing: From *Istanbul Contribution to Clinical Science* to *Turkish Journal of Hematology* (1951-2026)
Ahmet Muzaffer Demir; Edirne, Türkiye

Research Articles

204 Liver and Spleen Point Shear-Wave Elastography in Newly Diagnosed *BCR::ABL1*-Negative Myeloproliferative Neoplasms: Associations with Hematological Parameters and Bone Marrow Fibrosis Grade - A Prospective Cross-Sectional Study
Mehmet Taha Avcı, Melda Cömert, Demet Kiper, Gülgün Kavukçu, Ayhan Dönmez, Sadık Tamsel, Mine Hekimgil, Nazan Özsan, Süha Süreyya Özbek; İzmir, Türkiye

213 Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort Study
Shiqi Sun, Zejing Huang, Yunlong Tang, Weiying Gu, Leilei Wu, Fujun Shen; Yancheng, Suzhou, P.R. China

224 Is CMV PCR Monitoring Necessary in Patients with Hematological Malignancy Receiving Chemotherapy? A Prospective Single-Center Study
Zeynep Tuğba Karabulut, Tevfik Dündar, Serhat Çelik, Muzaffer Keklik, Ali Ünal, Selma Gökahmetoğlu, Leylagül Kaynar; Adana, Ankara, Kayseri, İstanbul, Türkiye

232 Asparaginase-Based Treatment Modifications and Their Effect on Pediatric Acute Lymphoblastic Leukemia Outcomes: A Single-Center Experience
Fatma Burçin Kurtipek, Dilek Kaçar, Turan Bayhan, Ayça Koca Yozgat, Özlem Arman Bilir, Namık Yaşar Özbek, Hüsniye Neşe Yaralı; Ankara, Türkiye

240 Role of ^{18}F-FDG PET/CT Metabolic Parameters in Treatment Response Evaluation and Prognostic Assessment of Hodgkin Lymphoma: A Retrospective Analysis
Hatice Uysal, Aziz Gültekin, Nil Güler, Nilay Şen Türk, Fikri Selçuk Şimşek, Tarık Şengöz, Doğangün Yüksel; Antalya, Denizli, Türkiye

Perspectives in Hematology

250 Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven Treatment
Vildan Özkocaman, Tuğcan Alp Kırkızlar, Gökhan Metan, Ömrüm Uzun, İbrahim Ethem Pınar, Fahir Özkalemkaş, Muhlis Cem Ar, Murat Akova; Bursa, Edirne, Ankara, İstanbul, Türkiye

262 Anticoagulation in Advanced Chronic Kidney Disease: Navigating Uncertainty
Arzu Velioğlu; İstanbul, Türkiye

Brief Reports

266 Increased Mast Cell Numbers in Bone Marrow of Patients with Myeloproliferative Neoplasms and Pruritus
Maud Hermans, Peter Westerweel, Thierry van den Bosch, Willem Dik, King Lam, Sanne Van Den Meerendonk, Francien Nederveen, Vincent van der Velden, Peter te Boekhorst; Rotterdam, Dordrecht, the Netherlands

Turkish Journal of Hematology
The Official Journal of the Turkish Society of Hematology

CONTENTS

274 National Perspectives on Academic CAR-T Cell Therapy in Türkiye: A Report from the Turkish Society of Hematology's Scientific Subcommittee on Cell and Gene Therapies (TSH-CGT SSC)
Meltem Kurt Yüksel, Koray Yalçın, Tuğrul Elverdi, Mahmut Yeral, Nur Akad Soyer, Şahika Zeynep Aki, Fatma Visal Okur, Muhlis Cem Ar; Ankara, İstanbul, Adana, İzmir, Türkiye

Images in Hematology

280 Hemolytic Anemia in a Newborn: Thinking About Infantile Pyknocytosis
Ines Maaloul, Ines Jedidi, Fatma Charfi, Imen Krichen, Nour Louati, Thouraya Kamoun; Sfax, Monastir, Tunisia

282 Visual Clues in Ocular Involvement of Acute Promyelocytic Leukemia
Rocío García-Risco, Paula García-Valentín, Marc Tort-Lacambra, Cristina Parés-Alfonso, Alba Jordán-Gascón, Tetiana Goncharova Simón, Elena Ros-Sánchez; Barcelona, Spain

Letters to the Editor

285 CMV PCR Monitoring for Hematological Malignancy
Hinpetch Daungsupawong, Viroj Wiwanitkit; Phonhong, Laos; Mohali, India

288 Thrombopoietin Receptor Agonist Exposure in Pregnancy: Not Always Without Fetal or Obstetric Complications
Ufuk Demirci, Mine Miskioğlu; Manisa, Türkiye

291 Interpreting Glycopeptide Escalation and Acute Kidney Injury with Caution
Shahzad Ali Jiskani, Muhammad Mustafa Asmat, Mariam Khan; Karachi, Pakistan

294 A Novel *MPIG6B* Gene Variant Identified in a Patient with Congenital Thrombocytopenia from Türkiye
Burcu Kılınç Oktay, Burak Durmaz, Simge Çınar Özel, Süheyla Ocak, Tülin Tiraje Celkan; Afyonkarahisar, İzmir, İstanbul, Türkiye

296 When All Else Fails: Complete Remission with Bortezomib in a Child with Life-Threatening Refractory Autoimmune Hemolytic Anemia
Fatih Demircioğlu, Zekai Avcı, İbrahim Akalın, Ayşe Sena Demircioğlu, Betül Tavil; İstanbul, Kocaeli, Türkiye

299 Dramatic Response to Elranatamab in a Patient with Large Plasmacytomas
Gülten Korkmaz; Ankara, Türkiye

302 Penile Plasmacytoma: A Rare Case
Özge Sönmez, Bircan Sönmez, Mehmet Sönmez; İstanbul, Trabzon, Türkiye

305 A Rare Case of POEMS-Associated Multicentric Castleman Disease with an Atypical Osteolytic Presentation
Tuphan Kanti Dolai, Shipla Roy, Kaustav Ghosh; Kolkata, India

308 Sustained Remission of More Than Five Years After Thalidomide-Cyclophosphamide-Prednisone Discontinuation in Idiopathic Multicentric Castleman Disease: A Single-Center Retrospective Study
Yue Dang, Yuhan Gao, Siyuan Li, Lu Zhang, Jian Li; Beijing, P.R. China

311 A Distinct Approach for Molecular ABO Typing: A Case of Serology-Genotype Discrepancy Within a Family
Zehra Narlı Özdemir, Fatma Liv, Özgür Şenol, Emre Can Gül, Aliye Arslan Gül, Ecegül Bengi; İzmir, Kocaeli, Türkiye